SEK0.42 -0.0 -3.2%
Last Trade - 16/04/21
| Market Cap | £14.3m |
| Enterprise Value | £11.2m |
| Revenue | £n/a |
| Position in Universe | 1484th / 1831 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 3.00 | 0.008 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Public Since | May 25, 2015 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | OMX Nordic Exchange Stockholm |
| Shares in Issue | 396,023,950 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Medicon Village Scheelevagen 2, LUND, 223 81, Sweden |
| Web | http://combigene.com/ |
| Phone | +46 40 6718906 |
| Contact | () |
| Auditors | Exset Revision |
As of 16/04/21, shares in Combigene AB are trading at SEK0.42, giving the company a market capitalisation of £14.3m. This share price information is delayed by 15 minutes.
Shares in Combigene AB are currently trading at SEK0.42 and the price has moved by -17.58% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Combigene AB price has moved by -36.13% over the past year.
Of the analysts with advisory recommendations for Combigene AB, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Combigene AB is Not available. You can view the full broker recommendation list by unlocking its StockReport.
Combigene AB is scheduled to issue upcoming financial results on the following dates:
Combigene AB does not currently pay a dividend.
Combigene AB does not currently pay a dividend.
Combigene AB does not currently pay a dividend.
To buy shares in Combigene AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Combigene AB are currently trading at SEK0.42, giving the company a market capitalisation of £14.3m.
Here are the trading details for Combigene AB:
Based on an overall assessment of its quality, value and momentum, Combigene AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Combigene AB are currently priced at SEK0.42. At that level they are trading at 0.448% discount to the analyst consensus target price of 0.00.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Combigene AB. Over the past six months, the relative strength of its shares against the market has been -54.48%. At the current price of SEK0.42, shares in Combigene AB are trading at -41.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Combigene AB.
Combigene AB's management team is headed by:
Here are the top five shareholders of Combigene AB based on the size of their shareholding:
